Emergence of Chloride as an Overlooked Cardiorenal Connector in Heart Failure

Amir Kazory1, Claudio Ronco2,3

  • 1Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, Florida, USA, amir.kazory@medicine.ufl.edu.

Blood Purification
|December 19, 2019
PubMed

Insights

Emerging research suggests serum chloride, not just sodium, is a key predictor of outcomes in heart failure (HF) and cardiorenal syndrome. Low chloride levels may indicate worse prognosis and offer new therapeutic targets.

Area of Science:

  • Cardiology
  • Nephrology
  • Clinical Biochemistry

Background:

  • Traditional heart failure (HF) management focused on sodium restriction.
  • Recent studies challenge the consistent benefits of severe salt restriction in HF.
  • Paradoxical adverse outcomes are observed with very low salt intake in advanced HF.

Purpose of the Study:

  • To review the emerging role of serum chloride in cardiorenal syndrome.
  • To explore chloride's prognostic value compared to sodium in HF.
  • To discuss potential mechanisms and therapeutic implications of chloride levels in HF.

Main Methods:

  • Review of contemporary studies and emerging data on serum chloride in HF.
  • Analysis of mechanistic links between hypochloremia and HF pathophysiology.
  • Exploration of clinical relevance and interpretation of chloride's prognostic role.

Main Results:

  • Serum chloride levels show significant independent prognostic value in various HF syndromes.
  • Hypochloremia is linked to adverse outcomes, potentially via renal tubular dysfunction and neurohormonal activation.
  • Chloride's prognostic impact may exceed that of sodium in certain HF populations.

Conclusions:

  • Serum chloride is a critical cardiorenal connector, challenging the sodium-centric view in HF.
  • Hypochloremia represents a potential therapeutic target for improving HF outcomes.
  • Future strategies for HF management should consider chloride levels for improved prediction and treatment.

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
751
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
849
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
211
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
615
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
394
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
319